SCHEDULE: State Street Reports 4.6% Stake in Travere Therapeutics

State Street Corporation has disclosed beneficial ownership of 4.6% of Travere Therapeutics Inc.'s common stock as of June 30, 2026.

Summary

• State Street Corporation has filed a Schedule 13G, indicating it beneficially owns 4,256,224 shares of Travere Therapeutics Inc. common stock.
• This represents 4.6% of the class of securities outstanding.
• The filing date is June 30, 2026, and the event requiring the filing is the acquisition or change in beneficial ownership.
• State Street Corporation holds sole voting power for 0 shares and shared voting power for 4,010,969 shares.
• It holds sole dispositive power for 0 shares and shared dispositive power for 4,256,224 shares.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a change in beneficial ownership without disclosing specific strategic reasons or significant shifts in investment strategy beyond standard institutional holdings.

Positives

• State Street Corporation's investment indicates confidence from a major institutional investor in Travere Therapeutics.
• The disclosure is a standard regulatory filing, ensuring transparency in ownership.

Negatives

• The filing does not provide specific details on the investment strategy or the rationale behind the ownership level.
• The significant portion of shares held with shared dispositive and voting power suggests potential for future portfolio adjustments.

Risks

• Potential for State Street Corporation to adjust its holdings, which could impact Travere Therapeutics' stock price.
• The filing does not offer insights into the long-term investment thesis, leaving its strategic implications for Travere Therapeutics unclear.

Future Outlook

This filing is a disclosure of current ownership and does not contain forward-looking statements or guidance regarding Travere Therapeutics' future performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that institutional ownership filings like this are common in the biotechnology sector, reflecting the significant capital requirements and investment cycles typical of drug development companies. The 4.6% stake by State Street, a major custodian and asset manager, suggests a notable, though not controlling, interest in Travere Therapeutics.

Stakeholder Impact

• Shareholders: Increased transparency regarding institutional ownership, potentially influencing investor sentiment.
• Travere Therapeutics Management: May need to engage with State Street Corporation on strategic matters if ownership levels warrant.
• Regulators: Compliance with disclosure requirements under the Securities Exchange Act of 1934.

Next Steps

• State Street Corporation will continue to hold or adjust its beneficial ownership of Travere Therapeutics Inc. common stock.
• Future filings may be required if ownership levels change significantly.

Key Dates

Keywords

Travere Therapeutics, State Street Corporation, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Holding